"Pfizer's Long-lasting RSV Vaccine Shows Promise in Older Adults"

Pfizer's RSV vaccine, Abrysvo, has shown to protect older adults for more than two seasons, with one dose being 77.8% effective against lower respiratory tract disease associated with RSV after the second season. The vaccine's efficacy slightly decreased from 89.9% after the first season. The FDA approved Abrysvo for use in older adults in May 2023, and the CDC recommended its use in June. The vaccine was also approved for use in infants through a dose administered to pregnant mothers during their third trimester.